Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2020-04-27 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
关于公司使用部分闲置募集资金及自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the use of idle raised funds and own funds for cash management. It details the investment purpose, amount, types of investments, authorization, risk analysis, and approvals from the board, supervisory committee, independent directors, and the sponsoring institution. It does not contain financial statements or quarterly/yearly financial results but rather focuses on the company's financing and capital management activities. The document is about the company's cash management and use of funds, which fits the category of Capital/Financing Update (CAP). The document length is about 5,151 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the appropriate classification is CAP with high confidence.
2020-04-27 Chinese
关于2020年度向银行申请综合授信额度的公告
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the company's application for a comprehensive credit facility from banks for the year 2020. It details the credit limits requested from various banks, the terms, and the approval process by the board of directors and the upcoming shareholder meeting. There are no financial statements, earnings data, or detailed financial analysis present. The document is focused on financing activities, specifically the application for credit lines. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2020-04-27 Chinese
2020年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2020 年第一季度报告正文" which translates to "2020 First Quarter Report". It contains detailed financial data such as revenue, net profit, cash flow, asset and liability balances, shareholder information, and other financial metrics for the first quarter of 2020. The length of the document is substantial (15,000 characters), and it includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). There is no indication that this is merely an announcement or a certification, and the content is substantive financial data and analysis. Therefore, the correct classification is IR with high confidence. Q1 2020
2020-04-27 Chinese
第三届监事会第十三次会议决议公告
Audit Report / Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 13th meeting of the third Supervisory Board of a company, including approval of the 2019 annual report, financial statements, profit distribution plan, internal control reports, and the 2020 first quarter report. It contains substantive content such as audit opinions, financial decisions, and internal control evaluations. The document is not merely an announcement of a report's publication but includes actual review and approval of financial reports and related matters. The presence of detailed financial and operational decisions and the supervisory board's review indicates this is a formal audit report or supervisory board report related to the annual financials and internal controls, rather than the full annual report itself or a simple announcement. Therefore, the best fitting category is Audit Report / Information (AR). The document length (3775 characters) and content support this classification rather than a report publication announcement or regulatory filing. FY 2019
2020-04-27 Chinese
独立董事关于第三届董事会第二十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion report related to various corporate governance and financial matters of the company, including profit distribution, internal control evaluation, use of raised funds, related party transactions, guarantees, appointment of senior management, and other compliance issues. It references the 2019 fiscal year and the 2020-2022 period for future plans. The document is not a full annual report or financial statement but rather a detailed governance and compliance opinion from independent directors on specific agenda items likely discussed at a board meeting or shareholder meeting. It does not contain comprehensive financial statements or earnings data, nor is it a simple announcement or certification. This type of document fits best under Board/Management Information (MANG) as it relates to board opinions and governance matters, including management appointments and internal controls. The document length is under 5,000 characters, but it contains substantive content beyond a mere announcement, so it is not an RPA or RNS. Therefore, the classification is MANG with high confidence.
2020-04-27 Chinese
东海证券股份有限公司关于公司使用部分闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a formal opinion from Donghai Securities regarding the use of idle raised funds by Kuihua Pharmaceutical Group Co., Ltd. for cash management. It references regulatory requirements and approvals, details the amount and purpose of the cash management, and confirms compliance with relevant laws and stock exchange rules. The document is a verification or audit opinion on the use of funds rather than a full financial report or announcement of voting results. It does not contain financial statements or earnings data, nor is it a simple announcement or presentation. Therefore, it fits best as an Audit Report / Information (AR) since it is a standalone audit opinion on the use of raised funds and compliance with regulations. FY 2020
2020-04-27 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.